A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models.
Saved in:
| Title: | A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models. |
|---|---|
| Authors: | Singh D; CN Bio Innovations Limited, Cambridge, United Kingdom., Deosarkar SP; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America., Cadogan E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Flemington V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Bray A; CN Bio Innovations Limited, Cambridge, United Kingdom., Zhang J; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America., Reiserer RS; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America., Schaffer DK; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America., Gerken GB; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America., Britt CM; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America., Werner EM; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America., Gibbons FD; DMPK, Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America., Kostrzewski T; CN Bio Innovations Limited, Cambridge, United Kingdom., Chambers CE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Davies EJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Montoya AR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hughes D; CN Bio Innovations Limited, Cambridge, United Kingdom., Fabre K; MPS Center of Excellence, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America., Wagoner MP; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America., Wikswo JP; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Departments of Biomedical Engineering and Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States of America., Scott CW; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America. |
| Source: | PLoS biology [PLoS Biol] 2022 May 26; Vol. 20 (5), pp. e3001624. Date of Electronic Publication: 2022 May 26 (Print Publication: 2022). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101183755 Publication Model: eCollection Cited Medium: Internet ISSN: 1545-7885 (Electronic) Linking ISSN: 15449173 NLM ISO Abbreviation: PLoS Biol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1545-7885 |
|---|---|
| DOI: | 10.1371/journal.pbio.3001624 |
